Tagrisso (osimertinib) - AstraZeneca
Kadcyla (ado-trastuzumab emtansine) - Roche
Vitrakvi (larotrectinib) - Bayer
relatlimab (BMS-986016) - BMS
Erivedge (vismodegib) - Roche
Paletan (pertuzumab biosimilar) - Sino Biopharm
omipalisib (GSK2126458) - GSK
Poherdy (pertuzumab-dpzb) - Organon, Shanghai Henlius Biotech
ABP 206 (nivolumab biosimilar) - Amgen
sapanisertib (CB-228) - Calithera
Trazimera (trastuzumab-qyyp) - Pfizer
Pertuvia (pertuzumab biosimilar) - Biocad
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Xalkori (crizotinib) - Pfizer
Tafinlar (dabrafenib) - Novartis
Hervelous (trastuzumab biosimilar) - Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy’s, Teva, Biosidus
Fakzynja (defactinib) - Verastem
Ibrance (palbociclib) - Pfizer
Balversa (erdafitinib) - J&J
fexagratinib (ABSK091) - Abbisko
Nivocad (nivolumab biosimilar) - Biocad
adavosertib (AZD1775) - AstraZeneca
Herceptin (trastuzumab) - Roche
Mektovi (binimetinib) - Pfizer
GSK2636771 - GSK
Truqap (capivasertib) - AstraZeneca
ulixertinib (BVD-523) - BioMed Valley Discoveries
Aliqopa (copanlisib) - Bayer
ipatasertib (RG7440) - Roche
dasatinib - Generic mfg.
taselisib (GDC-0032) - Roche
sunitinib - Generic mfg.
Mekinist (trametinib) - Novartis, BeOne Medicines
Gilotrif (afatinib) - Boehringer Ingelheim
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov) - Sep 30, 2026 - P2 | N=6452 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027 
Biomarker • Trial completion date • Trial primary completion date • Bladder Cancer • Brain Cancer • Breast Cancer • Cervical Cancer • Colon Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Glioblastoma • Glioma • Head and Neck Cancer • Hematological Malignancies • Hormone Receptor Positive Breast Cancer • Kidney Cancer • Liver Cancer • Lung Cancer • Lymphoma • Melanoma • Multiple Myeloma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Refractory Ovarian Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Thyroid Gland Carcinoma • Uterine Cancer • CD4 • MSI
http://clinicaltrials.gov/ct2/show/NCT02465060
 
Sep 30, 2026
 
Prev Next